Friday, 16 October 2026European Markets

TECHSTEP Stock 14.04% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with TECHSTEP (TECH.OL) rising 14.04% to kr1.30 on Thursday, following the last session's upward trend. Oslo Børs Benchmark Index_GI slid 0.02% to kr1,160.00, after five consecutive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

TECHSTEP's last close was kr1.14, 65.45% under its 52-week high of kr3.30.

About TECHSTEP

Techstep ASA operates as a mobile technology enabler in Norway, Sweden, Denmark, and Poland. It offers mobile hardware, service, support, and mobility consultancy services; software as a service, as well as mobile expense management modules; and financing and remarketing services. The company also provides industry-leading cloud-based PBX solutions and enterprise mobility management services, including mobile security, system design, implementation, and mobile device management. In addition, it develops and provides enterprise mobility software and solutions for the customers in the transportation, logistics, and public safety sectors, as well as offers mobile device lifecycle management solutions. The company was founded in 2016 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, TECHSTEP has a trailing twelve months EPS of kr-0.135.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -12.18%.

Moving Average

TECHSTEP's value is way above its 50-day moving average of kr1.13 and way below its 200-day moving average of kr1.64.

Yearly Top and Bottom Value

TECHSTEP's stock is valued at kr1.30 at 21:33 EST, way under its 52-week high of kr3.30 and way higher than its 52-week low of kr0.96.

Sales Growth

TECHSTEP's sales growth for the current quarter is 4.7%.

More news about TECHSTEP (TECH.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com